Don’t write off this falling pharma stock just yet, brokerages say it can offer double-digit returns
Last week, BofA Securities maintained a ‘buy ‘rating on the drug maker with a target price of Rs 3,200 per share. This target suggests a potential 35 per cent upside for the stock. BofA said export data showed signs of recovery and that normalized run-rate likely in 2HFY23.
